CVS Health Corporation $CVS Shares Sold by Davis Selected Advisers

Davis Selected Advisers cut its stake in CVS Health Corporation (NYSE:CVS) by 1.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,403,641 shares of the pharmacy operator’s stock after selling 183,149 shares during the quarter. CVS Health comprises about 4.5% of Davis Selected Advisers’ investment portfolio, making the stock its 6th biggest position. Davis Selected Advisers owned 0.90% of CVS Health worth $859,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Harbor Capital Advisors Inc. raised its stake in shares of CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares during the period. Corundum Trust Company INC acquired a new stake in CVS Health during the 3rd quarter valued at $29,000. Front Row Advisors LLC grew its holdings in CVS Health by 436.5% during the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 371 shares in the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new stake in CVS Health during the 2nd quarter worth $36,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS Health stock opened at $73.03 on Thursday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $85.15. The firm’s 50-day simple moving average is $77.83 and its 200-day simple moving average is $77.83. The firm has a market cap of $92.91 billion, a PE ratio of 52.92, a price-to-earnings-growth ratio of 0.78 and a beta of 0.49.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same period last year, the firm earned $1.19 earnings per share. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio is currently 192.75%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Truist Financial set a $100.00 price objective on shares of CVS Health in a research report on Wednesday, December 10th. Argus cut their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Mizuho increased their price target on CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Wolfe Research lowered their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Finally, UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Twenty analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.